Heifets, Boris D. http://orcid.org/0000-0003-1474-0379
Olson, David E. http://orcid.org/0000-0002-4517-0543
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM128997)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA056365)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH130591)
Article History
Received: 9 March 2023
Revised: 10 July 2023
Accepted: 11 July 2023
First Online: 24 July 2023
Competing interests
: BDH is on the scientific advisory boards of Osmind and Journey Clinical and is a consultant for Clairvoyant Therapeutics and Vine Ventures, all unrelated to the present work. DEO is a co-founder of Delix Therapeutics, Inc., serves as the Chief Innovation Officer and Head of the Scientific Advisory Board, and has sponsored research agreements with Delix Therapeutics. Delix Therapeutics has licensed technology from the University of California, Davis.